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Abstract
Objective: Women's sleep at menopause is widely reported to be problematic. The Insomnia 
Severity Index is a commonly used tool for quantifying sleep problems in clinical and research 
settings, but psychometric properties in menopausal women have not been reported. Our study aim 
was to examine the factor structure of the Insomnia Severity Index in a large and diverse sample of 
midlife women with hot flashes.
Methods: Baseline data were from 899 women enrolled in one of the three clinical trials using 
similar entry criteria conducted by the Menopause Strategies Finding Lasting Answers to 
Symptoms and Health (MsFLASH) research network. We conducted confirmatory factor analyses 
for the total sample and within strata defined by race/ethnicity (Black and White women).
Corresponding author: Julie L. Otte, PhD, RN, OCN, 600 Barnhill Drive, NU W401, Indianapolis, IN 46202 USA; Phone (317) 
274-0886; Fax (317) 278-1856; jlelam@iupui.edu. 
Financial disclosures/conflicts of interest: Drs. Carpenter and Rand are funded under an Independent Grant for Learning and 
Change from Pfizer, Inc (2017–2018). Dr. Carpenter consults for QUE Oncology and Astellas Pharma, Inc. Dr. Joffe receives grant 
support from NIH, Merck, Pfizer, Pfizer, QUE Oncology and consults for KaNDy and Sojournix; and her spouse is a Merck employee. 
The rest of the authors have no conflicts to report.
HHS Public Access
Author manuscript
Menopause. Author manuscript; available in PMC 2020 August 01.
Published in final edited form as:













Results: The Insomnia Severity Index had two factors in the total sample. The 2-factor structure 
was consistent across Black and White women, with the exception of one item “Difficulty falling 
asleep”.
Conclusions: The Insomnia Severity Index in midlife women with hot flashes is composed of 
two factors that capture dimensions of the insomnia severity and daytime impact. The instrument 
is a psychometrically sound scale appropriate for use in research and clinical practice to capture 
the severity and daytime impact of insomnia symptoms in diverse samples of midlife women with 
hot flashes. An abbreviated screening of two items could be considered to determine if further 
evaluation is needed of sleep complaints.
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Introduction
Extensive research shows that midlife women report poor sleep during various stages of the 
menopause transition and postmenopause.1–6 For example, at least 48–50% of women with 
hot flashes experience problems with nighttime sleep during late menopause and early post-
menopause.3,5–7 Self-reported sleep problems are often characterized as symptoms of 
insomnia such as the inability to fall asleep, remain asleep, and feel rested during the day.
8–11 Insomnia symptoms are highly associated with daytime fatigue and overall poor quality 
of life. 10–14 Thus, it is imperative that clinicians and researchers have well-validated 
measures of insomnia symptoms to clinically diagnose and treat primary and secondary 
insomnia disorders.13
The Insomnia Severity Index (ISI) is widely-used to quantify self-reported insomnia 
symptoms in clinical practice and research. It is a 7-item scale that requires under ten 
minutes to complete and score. However, use in clinical practice can be limited due to 
limited resources, competing demands, and time constraints. Scores indicate no, mild, 
moderate, or severe insomnia over the past 2 weeks, with higher scores indicating more 
severe insomnia.15 The scale has been used in adults16,17 and teenagers18 and has been 
translated to over 50 languages such as Chinese,19 Spanish20, and Arabic.21
The research team that created the ISI did not conduct an exploratory factor analysis in the 
initial psychometric evaluation studies which limited the depth of understanding regarding 
of the theoretical structure of insomnia. There are only a small number of studies that have 
examined ISI psychometrics and/or factor structure with the original English-language 
version of the scale, and none of these studies were specific to menopausal women.
15,18,22–24 Factor structures reported contained models of two or three-factor structures. Two 
factor models included a factor of insomnia symptoms and factor of the impact of insomnia 
symptoms.18,22,23 Three factor models include a factor structure of severity of symptoms, 
impact of poor sleep, and satisfaction with sleep.15,24 Because the factor structures of 
validated questionnaires can vary by population (e.g., age, gender, race), the purpose of this 
study was to examine the factor structure of the ISI using data from midlife women with hot 
flashes enrolled in the MsFLASH menopausal symptom treatment trials to determine the 
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variable dimensions on insomnia in this population. We sought to evaluate the factor 
structure in the overall sample as well as whether it varied between women according to race 
(White vs. Black). Although women were not selected for the first three MsFLASH trials 
based on a-priori self-reports of sleep problems, 70% of the sample reported sleep problems 
at baseline, further supporting the relationship between hot flashes and sleep complaints. 
Based on the factor structure we will examine if an abbreviated scale is possible to use in 
clinical practice when assessing insomnia symptoms in this population.
Methods
Design
We collated baseline data from 899 women enrolled in the MsFLASH 01, 02, and 03 trials.
25–32 Common inclusion criteria across studies were 14 or more hot flashes per week, peri- 
or post-menopausal, age 40–62, and in good general health. Women were recruited from 
July, 2009 through October, 2012. Recruitment methods included mass mailings using 
purchased mailing lists and health plan enrollment files. Interested women maintained a 
daily hot flash diary for two weeks; if they continued to be eligible, they took part in two 
baseline assessments scheduled one week apart. All trials were reviewed by institutional 
review boards and informed consent was obtained for all participants. The details of these 
trials have been extensively described in other reports.25–32
Measures
Women reported basic demographic information at baseline. These data included race, 
ethnicity, age, education, and smoking history. Study staff measured women’s height and 
weight in the clinics for calculations of body mass index. Women completed the ISI as part 
of a larger packet of baseline questionnaires.
Vasomotor frequency, severity, and bother were assessed using daily diaries. Participants 
completed the paper-based diaries upon awakening and before falling asleep. Severity of 
daytime and nighttime hot flashes was rated from 0 (mild) to 2 (severe). Bother of daytime 
and nighttime hot flashes was rated from 0 (not at all) to 3 (a lot).
The 7-item ISI evaluates perceived severity of insomnia over the past 2 weeks. Items are 
scored using a Likert-type scale with 5 response options (0=not at all to 4=very much). Total 
scores are obtained by summing items, with total scores ranging from 0 to 28. Higher scores 
indicate greater perception of insomnia severity. Reliability and validity have been 
established in healthy individuals (n=145 Cronbach’s alpha=0.74) and those with chronic 
illnesses (n=1634, Cronbach’s alpha=0.90).15,23
Statistical analysis
For demographic variables, we used absolute and relative frequencies to describe categorical 
variable and median and interquartile range for continuous variables. To compare 
demographic variables between Black and White participants, we used Pearson’s chi-
squared test for categorical variables and the Mann-Whitney test for continuous variables..
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We performed a series of confirmatory factor analyses based on unweighted least squares 
(ULS) estimation of the model parameters. We chose ULS estimation because the items of 
the ISI scale were ordinal variables and thus the usual maximum likelihood estimation was 
not applicable. Other popular approaches to deal with ordinal items are weighted least 
squares (WLS) and diagonally weighted least squares (DWLS) estimation methods. 
However, ULS performance has been shown to be superior in finite samples to that of WLS 
and DWLS estimation.33 Good model fit was defined as values of both Tucker-Lewis fit 
Index (TLI) and Comparative Fit Index (CFI) greater than 0.95, a Root Mean Square Error 
of Approximation (RMSEA) value smaller than 0.06, and a Standardized Root Mean Square 
Residual (SRMR) value smaller than 0.08.34
The assessment of measurement invariance between Black and White women was based on 
a sequence of nested-model comparisons using scale items. Following the recommendation 
by Cheung and Rensvold (2002),35 we used the CFI measure for comparing nested models 
between Black and White women. However, unlike Cheung and Rensvold, we performed 
bootstrap hypothesis tests to statistically evaluate the potential differences between the CFI 
measures for pairs of nested models that were considered in the invariance analysis.36 This 
choice was crucial because, to our knowledge, the asymptotic distribution of the CFI 
estimator has not been studied, and therefore there is no available parametric approach for 
hypothesis testing. To compare differences in the intercepts of individual items between 
Black and White women we performed formal Wald tests for the differences between each 
item’s intercepts, using the appropriate variance components of the estimated variance 
covariance matrix for the fitted model for the strong/scalar invariance and applied the 
Bonferroni correction for type I error inflation due to multiple comparisons.
All statistical analyses except for the confirmatory factor analysis were performed using 
STATA 14 for Windows (STATACorp LLC, College Station, TX). The free statistical 
software package called R was used to perform the confirmatory factor analysis and the 
evaluation of construct invariance.37
Results
In total, 899 participants from 3 MsFLASH studies were included in the analysis. Of them, 
530 (59.0%) were White, 288 (32.0%) were Black, 78 (8.7%) were American-Indian, Asia/
Pacific Islanders or other, while ethnicity information for 3 (0.3%) participants was missing. 
For this overall sample, most participants were educated beyond high school, were never 
smokers, were overweight, and had subthreshold or higher insomnia (see Table 1). When 
comparing only the subgroups of White and Black women, Black women were younger, had 
higher BMI, higher VMS symptomatology, and higher ISI severity (see Table 1).
Results of the factor analysis in the overall sample are shown in Table 2 and Figure 1. Fit 
indices shown in Table 2 indicate that a one-factor model did not provide good fit according 
to the RMSEA. In contrast, a 2-factor model met all the criteria of a good fit. The 2-factor 
model (severity and impact of symptoms) is depicted along with the estimated factor 
loadings, correlation between the factors, and the residual standard errors in Figure 1.
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Results of the ISI measurement invariance are shown in Table 3. The CFI for configural 
invariance was excellent for a 2-group, 2-factor model with all model parameters allowed to 
freely vary between groups. When the factor loadings were constrained to be equal for Black 
and White women, the CFI did not vary significantly. These results show the ISI factor 
structure did not differ by race.
When the intercepts were constrained to be equal across the two groups, however, the model 
fit was significantly inferior, suggesting a difference in at least one item intercept. Additional 
analyses not shown in the table showed one difference between racial groups. When we 
compared differences of the intercepts of the individual items between Black and White 
women, the item “difficulty falling asleep” (p<0.001) showed a partial strong/scalar non-
invariance of the ISI construct across race. We further considered the fit and the invariance 
properties of the 2-factor model for the reduced 6-item ISI scale, with the item “difficulty 
falling asleep” omitted. The fit of the 2-factor model based on the reduced scale was good 
(CFI=0.996, TLI=0.993, RMSEA=0.055, SRMR=0.034). More importantly, there was no 
evidence for non-invariance of that model between Black and White women, based on the 
reduced 6-item scale meaning the scale performed the same in both groups.
Discussion
The study results show that a 2-factor model (Symptom Severity and Daytime Impact) is a 
good fit for this sample of midlife women with hot flashes. Although this is the first analysis 
to solely focus on the ISI factor structure in women, our findings are similar to previous 
research studies that found similar 2-factor models that included mixed gender samples.
19,22,23 This is the first paper to focus solely on women in this specific age group with 
insomnia symptoms and hot flashes with more extensive analyses to determine factor 
structure.
The ISI was developed by the original authors to provide a reliable and valid brief scale to 
screen for insomnia and provide a tool for evaluation of treatment outcomes.16 However no 
factor structure was presented in that original article. Typically the instrument is presented 
using the established cutoff scores and clinically significant change scores to determine 
incidence of insomnia and treatment response. Subsequent researchers have added to the 
dimensionality of the measure by conducting factor analysis suggesting that the measure can 
perform differently in various populations.22 Specifically, the items from the questionnaire 
fall into the following 2-factor model. Factor 1 includes items 1–4 of the questionnaire that 
focus on the symptoms of insomnia: difficulty falling asleep, staying asleep, waking too 
early, and satisfaction with current sleep. Factor 2 includes natural content on the impact of 
the insomnia symptoms. This is an important outcome as clinicians use both symptoms and 
impact of symptoms to diagnose and recommend treatment.
We found that the 2-factor structure and factor inter-correlations were consistent between 
Black and White women, meaning that the scale performed similarly in both groups. 
However, comparisons showed one difference between the models. The ‘difficulty falling 
asleep’ item did not perform the same across two racial groups. This particular item was the 
weakest loading item on the Symptom Severity factor, suggesting the other three items 
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within this factor were better indicators of that construct. After removing this item, the 
resulting model showed good fit and performed consistently across racial groups. This 
suggests consideration should be given to using the 6-item version of the ISI to allow for 
meaningful comparisons of insomnia symptoms between Black and White women. The goal 
is to have ISI models that measure insomnia symptoms equally well in both racial groups in 
order to enable cross-group quantitative comparisons and ensure proper interpretation of 
results. Clinically, this item omission is unlikely to affect the accurate assessment of 
insomnia symptoms. The 6-item version of the ISI is flexible and appropriate for use in both 
groups of women.
Study findings have important implications for scoring the ISI in clinical practice and 
research. For clinical purposes, it would be acceptable to report a single ISI score. The high 
correlation between the two underlying factors suggests that items might not need to be 
scored and reported as two separate scores to be clinically meaningful. Clinically, having an 
abbreviated scale or single item questions could be beneficial as it reduces the time of 
administering and scoring the scale. However, for research purposes, it is more descriptive to 
report scores for each of the two factors. In particular, in intervention studies, it may be 
beneficial to report scores for each factor to determine the differential impact of 
interventions on each factor. This is especially important when there could be a disconnect 
between symptom severity and the impact on daytime outcomes such as individuals that did 
not sleep but do not always rate daytime outcomes to be detrimentally impacted or vice 
versa.
Lastly, for clinicians looking for an abbreviated scale or single items to use during a clinical 
visit to assess sleep, two items emerged that could provide an initial screening for father 
exploration into sleep complaints. Looking at the items within each factor separately, single 
items emerged within each factor that could provide some indication of insomnia severity 
and daytime impact. For symptom severity, item 1 ‘difficulty staying asleep’ had the highest 
correlation with the factor score. For impact of insomnia, the item 6 that evaluates how 
worried/distressed the person is about sleep could be the best indicator of how daytime 
functioning is impacted. In the prior research studies that supported a 3-factor structure, the 
sleep satisfaction item loaded into a different factor.15,24 In our analyses, the sleep 
satisfaction loaded onto the nighttime symptoms severity factor. It is unclear why this 
particular item loads differently compared to previous literature but could be attributed to the 
particular sample and how that item is interpreted.
Conclusion
The incidence and prevalence of sleep complaints in women continue to be high, especially 
in midlife women with vasomotor symptoms, although women continue to be under-
represented in sleep research.9 Using existing data, we performed the first factor analysis of 
the ISI in midlife women. Findings suggest the ISI performed equally well in both Black and 
White women. Clinicians can also consider using an abbreviated screening of the two items 
suggested above in this population of women (items 1 “Difficulty staying asleep” and item 6 
“How Worried/Distressed are you about your current sleep problem”) to determine if further 
exploration is needed regarding sleep complaints. For research, we recommend scoring 
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based on a two-factor structure to understand both symptom severity and daytime impact, 
two important outcomes in descriptive and intervention research. In the clinical setting, we 
recommend scoring based on a one-factor structure (traditional scoring) or considering 
screening for insomnia using only the two items most highly correlated with each factor 
score. Clinically having an overall severity rating using the one factor or total score is 
optimal for ease of use and continues to provide information on insomnia severity for 
treatment.
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The 2-factor model of the Insomnia Severity Index in midlife women
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Age at screening <0.001
 < 50 73 (8.1) 39 (13.5) 29 (5.5)
 50 - 54 404 (44.9) 139 (48.3) 234 (44.2)
 55 - 59 319 (35.5) 88 (30.6) 199 (37.5)
 >= 60 103 (11.5) 22 (7.6) 68 (12.8)
Education <0.001
 <=High school diploma or general education degree 114 (12.7) 66 (22.9) 37 (7.0)
 Post-high school 310 (34.6) 128 (44.4) 150 (28.4)
 College graduate 473 (52.7) 94 (32.6) 341 (64.6)
Smoking <0.001
 Never 507 (56.6) 136 (47.2) 325 (61.7)
 Past 255 (28.5) 66 (22.9) 161 (30.6)
 Current 134 (15.0) 86 (29.9) 41 (7.8)
BMI (kg/m2) <0.001
 < 25 295 (33.1) 45 (15.7) 219 (41.8)
 25 - 29.9 323 (36.3) 96 (33.6) 198 (37.8)
 >= 30 273 (30.6) 145 (50.7) 107 (20.4)
ISI Sleep Score 0.006
 None (0-7) 251 (28.4) 84 (30.2) 140 (26.7)
 Subthreshold (8-14) 358 (40.5) 101 (36.3) 240 (45.7)
 Moderate (15-21) 235 (26.6) 73 (26.3) 130 (24.8)
 Severe (22-28) 40 (4.5) 20 (7.2) 15 (2.9)
Median (IQR) Median (IQR) Median (IQR) p
Age at screening 54.0 (52.0, 57.0) 53.0 (51.0, 56.0) 55.0 (52.0, 58.0) <0.001
BMI (kg/m2) 27.1 (23.7, 31.1) 30.1 (26.8, 33.4) 25.9 (22.9, 28.9) <0.001
VMS Frequency 7.1 (5.2, 10.1) 7.4 (5.4, 10.5) 7.1 (5.0, 9.9) 0.032
VMS Severity 1.0 (0.7, 1.3) 1.2 (0.9, 1.6) 0.9 (0.7, 1.2) <0.001
VMS Bother 2.0 (1.6, 2.3) 2.2 (1.9, 2.6) 1.9 (1.5, 2.2) <0.001
ISI Sleep Score 11.0 (7.0, 16.0) 12.0 (6.0, 16.0) 11.0 (7.0, 15.0) 0.468
BMI=body mass index; ISI=Insomnia Severity Index; IQR= interquartile range; VMS=vasomotor symptoms (hot flashes, night sweats); VMS 
severity rated 0 mild to 2 severe; VMS bother rated 0 not at all to 3 a lot.
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Table 2:
Fit Indices of Different Insomnia Severity Index Factor Models
Model CFI TLI RMSEA RMSEA90% CI SRMR
1-Factor 0.990 0.986 0.076 (0.061, 0.091) 0.050
2-Factor 0.997 0.994 0.047 (0.030, 0.064) 0.033
CFI= Comparative Fit Index; TLI= Tucker-Lewis fit Index; RMSEA=Root Mean Square Error of Approximation; SRMR= Standardized Root 
Mean Square Residual
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Table 3:
Evaluation of Invariance of Insomnia Severity Index Between Black and White women
CFI ΔCFI p
Invariance
 Configural 0.997 NA NA
 Loadings 0.990 0.007 0.080
 Intercepts 0.986 0.004 0.010
 Means 0.985 0.001 0.396
CFI= Comparative Fit Index; ΔCFI=Change in Comparative Fit Index
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